

# Carmelo Scarpignato

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/308938/carmelo-scarpignato-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

238  
papers

6,220  
citations

40  
h-index

69  
g-index

332  
ext. papers

7,264  
ext. citations

4.5  
avg, IF

6.12  
L-index

#	Paper	IF	Citations
238	Review article: rethinking the "ladder" approach to reflux-like symptom management in the era of PPI "resistance": a multidisciplinary perspective.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	0
237	Acid-Lowering Drugs for the Treatment of Gastro-esophageal Reflux Disease <b>2022</b> , 273-305		
236	Non-Absorbable Antibiotics <b>2022</b> , 209-234		
235	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. <i>Digestive Diseases</i> , <b>2021</b> , 39, 119-139	3.2	36
234	Cancer Prevention in Patients with GERD and Barrett's Esophagus. <i>Esophageal Medicine</i> . <i>Foregut</i> , <b>2021</b> , 1, 50-62		0
233	Management of perforated diverticulitis with generalized peritonitis. A multidisciplinary review and position paper. <i>Techniques in Coloproctology</i> , <b>2021</b> , 25, 153-165	2.9	3
232	Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. <i>Current Treatment Options in Gastroenterology</i> , <b>2021</b> , 19, 94-132	2.5	3
231	Colonic diverticular disease. <i>Nature Reviews Disease Primers</i> , <b>2020</b> , 6, 20	51.1	40
230	S1368 Vonoprazan-Based Dual Therapy and FDA-Approved H. pylori Eradication Regimens: A Comparison of the Available Pooled Data. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, S690-S691	0.7	1
229	Eosinophilic Esophagitis: Diagnosis and Current Management. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2020</b> , 29, 85-97	1.4	10
228	Combined Treatment with Polynucleotides and Hyaluronic Acid Improves Tissue Repair in Experimental Colitis. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	6
227	Potential proton pump inhibitor-related adverse effects. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1481, 43-58	6.5	8
226	Eosinophilic esophagitis: updates on key unanswered questions. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1481, 30-42	6.5	3
225	Ageusia, gastrointestinal symptoms and marked asthenia in late December. A single case report with positive SARS-Cov2 IgG in Italy. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 97, 352-353	10.5	1
224	Pharmacologic treatment of GERD: Where we are now, and where are we going?. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1482, 193-212	6.5	7
223	Gastrointestinal pharmacology: practical tips for the esophagologist. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1481, 90-107	6.5	6
222	Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus. <i>Advances in Therapy</i> , <b>2019</b> , 36, 2618-2637	4.1	22

221	Expert Consensus on Clinical Use of an Orally Administered Dexketoprofen Plus Tramadol Fixed-Dose Combination in Moderate-To-Severe Acute Pain: A Delphi Study. <i>Advances in Therapy</i> , <b>2019</b> , 36, 3174-3185	4.1	11
220	Antiemetic Drug Use in Children: What the Clinician Needs to Know. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2019</b> , 68, 466-471	2.8	7
219	Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , <b>2019</b> , 43, 331-343	5.5	18
218	Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. <i>Current Gastroenterology Reports</i> , <b>2019</b> , 21, 55	5	17
217	Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 23-29	1.4	1
216	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 57-66	1.4	7
215	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 39-44	1.4	0
214	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 11-16	1.4	0
213	The "DICA" endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 23-27	1.4	1
212	The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. <i>Current Opinion in Gastroenterology</i> , <b>2019</b> , 35, 344-355	3	15
211	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 190-205	3.3	36
210	Revisiting Montreal: New Insights into Symptoms and Their Causes, and Implications for the Future of GERD. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 414-421	0.7	21
209	Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology</i> , <b>2018</b> , 154, 500-514	13.3	196
208	Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1261-1269	6.1	29
207	Searching for a definition for pharmacologically refractory constipation: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 564-575	4	10
206	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks <b>2018</b> , 269-291		3
205	Letter: can the overall gastrointestinal safety of celecoxib be extended to all COX-2-selective agents?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 108-110	6.1	0
204	Diagnosis and Treatment of Colonic Diverticular Disease: Position Paper of the Romanian Society of Gastroenterology and Hepatology. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2018</b> , 27, 449-457	1.4	3

203	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO3-5-28	0	
202	Symptomatic Uncomplicated Diverticular Disease: Chronic Abdominal Pain in Diverticulosis Is Not Enough to Make the Diagnosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 2001-2002	6.9	8
201	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1340	5.6	24
200	Potent Acid Suppression with PPIs and P-CABs: What's New?. <i>Current Treatment Options in Gastroenterology</i> , <b>2018</b> , 16, 570-590	2.5	19
199	Reply. <i>Gastroenterology</i> , <b>2018</b> , 155, 1272-1273	13.3	
198	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. <i>Therapeutic Advances in Gastroenterology</i> , <b>2018</b> , 11, 1756284818771305	4.7	25
197	Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 604-616	6.1	100
196	Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 631-642	6.1	38
195	An expert consensus definition of failure of a treatment to provide adequate relief (F-PAR) for chronic constipation - an international Delphi survey. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 434-442	6.1	6
194	Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1165-1173	2.5	42
193	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. <i>Gastroenterology</i> , <b>2017</b> , 152, 980-982.e3	13.3	42
192	Reply. <i>Gastroenterology</i> , <b>2017</b> , 153, 612-613	13.3	1
191	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A adenosine receptors. <i>Purinergic Signalling</i> , <b>2017</b> , 13, 497-510	3.8	24
190	Efficacy of Rifaximin to Eradicate Small Intestine Bacterial Overgrowth and to Get Symptom Relief: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, S647	0.7	
189	Constant Increase in Primary Resistances of Helicobacter pylori strains and Their Role in the Effectiveness of Sequential Therapy: A Lesson From a 5-Year Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, S664	0.7	
188	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. <i>Drug Development and Industrial Pharmacy</i> , <b>2016</b> , 42, 332-9	3.6	12
187	Adverse Effects of Nonsteroidal Anti-inflammatory Drugs on the Cardiovascular System <b>2016</b> , 61-89		1
186	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. <i>Journal of Controlled Release</i> , <b>2016</b> , 239, 203-10	11.7	8

185	Management of Patients With Diverticulosis and Diverticular Disease: Consensus Statements From the 2nd International Symposium on Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S101-7	3	21
184	Preface to the Proceedings of the 2nd International Symposium on Diverticular Disease of the Colon. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S1	3	2
183	Prognostic Role of the Endoscopic Classification "DICA". <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S16-9	3	4
182	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 604-13	5.3	24
181	Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. <i>Pharmacological Research</i> , <b>2016</b> , 104, 108-14	10.2	37
180	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , <b>2016</b> , 104, 186-96	10.2	22
179	Probiotics for the Treatment of Symptomatic Uncomplicated Diverticular Disease: Rationale and Current Evidence. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S70-3	3	8
178	Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S64-9	3	45
177	Current Management of Patients With Diverticulosis and Diverticular Disease: A Survey From the 2nd International Symposium on Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50 Suppl 1, S97-S100	3	11
176	Adherence with regulatory resolutions on prevention of NSAIDs-related gastrointestinal injury in Italy. <i>International Journal of Clinical Pharmacy</i> , <b>2016</b> , 38, 829-37	2.3	1
175	Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. <i>BMC Medicine</i> , <b>2015</b> , 13, 55	11.4	119
174	Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. <i>Digestive Diseases</i> , <b>2015</b> , 33, 68-76	3.2	46
173	Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 335-8	2.5	2
172	Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 1-11	4.4	12
171	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , <b>2014</b> , 35, 633-658	0.2	0
170	Italian consensus conference for colonic diverticulosis and diverticular disease. <i>United European Gastroenterology Journal</i> , <b>2014</b> , 2, 413-42	5.3	112
169	Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women. <i>European Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 52, 125-31	5.1	2
168	NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 348, 86-95	4.7	36

167	Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. <i>Pharmacological Research</i> , <b>2014</b> , 85, 39-44	10.2	25
166	Long acting release-octreotide as "rescue" therapy to control angiodysplasia bleeding: A retrospective study of 98 cases. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 688-94	3.3	27
165	Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. <i>PLoS ONE</i> , <b>2014</b> , 9, e116253	3.7	34
164	Gastrointestinal Drugs. <i>Side Effects of Drugs Annual</i> , <b>2014</b> , 36, 539-560	0.2	1
163	Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , <b>2014</b> , 171, 1314-29	8.6	24
162	Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study. <i>Gastroenterology</i> , <b>2013</b> , 17, 3244-8	13.3	6
161	Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. <i>BMJ, The</i> , <b>2013</b> , 347, f4587	5.9	178
160	Poor effectiveness of PPIs in non-erosive reflux disease: the truth in the end!. <i>Neurogastroenterology and Motility</i> , <b>2013</b> , 25, 707	4	2
159	Commentary: Towards an effective and safe treatment of small intestine bacterial overgrowth. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1409-10	6.1	10
158	Caustic injury of the upper gastrointestinal tract: a comprehensive review. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3918-30	5.6	209
157	Piroxicam- $\beta$ -cyclodextrin: a GI safer piroxicam. <i>Current Medicinal Chemistry</i> , <b>2013</b> , 20, 2415-37	4.3	26
156	Commentary: towards a cardiac safe prokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 1243-4	6.1	5
155	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!. <i>Neurogastroenterology and Motility</i> , <b>2012</b> , 24, 697-704	4	33
154	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , <b>2012</b> , 34, 555-578	0.2	1
153	Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 133-7	3.7	15
152	Nonsteroidal anti-inflammatory drug-activated gene-1 plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2012</b> , 342, 140-9	4.7	13
151	Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 440-2	6.9	20
150	Features and management of esophageal corrosive lesions in children in Sierra Leone: lessons learned from 175 consecutive patients. <i>Journal of Pediatric Surgery</i> , <b>2011</b> , 46, 1739-45	2.6	16

149	Gastrointestinal drugs. <i>Side Effects of Drugs Annual</i> , <b>2011</b> , 33, 741-767	0.2	1
148	Evaluation of clinical outcome after laparoscopic antireflux surgery in clinical practice: still a controversial issue. <i>Minimally Invasive Surgery</i> , <b>2011</b> , 2011, 725472	1.3	6
147	Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2011</b> , 23, 845-51	2.2	23
146	Barrett's esophagus: proton pump inhibitors and chemoprevention II. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 114-39	6.5	7
145	Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6, 35-9	3.7	9
144	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 818-22	2.4	53
143	Pharmaceutical principles of acid inhibitors: unmet needs. <i>Digestive Diseases</i> , <b>2011</b> , 29, 469-75	3.2	2
142	Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. <i>Gastroenterology Clinics of North America</i> , <b>2010</b> , 39, 433-64	4.4	153
141	PWE-079 Use of antisecretory medication after antireflux surgery for patients with gastro-oesophageal reflux disease: a systematic review of non-randomised studies. <i>Gut</i> , <b>2010</b> , 59, A116.3-A117 <sup>1</sup>	19.3	17 <sup>1</sup>
140	Rifaximin in the management of colonic diverticular disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2009</b> , 3, 585-98	4.2	17
139	New therapeutic approaches for management of sport-induced muscle strains. <i>Advances in Therapy</i> , <b>2009</b> , 26, 1072-83	4.1	12
138	Myths and facts in the use of anti-inflammatory drugs. <i>Annals of Medicine</i> , <b>2009</b> , 41, 423-37	1.5	33
137	Corrosive oesophageal strictures in children: outcomes after timely or delayed dilatation. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 263-8	3.3	35
136	Caustic ingestion in children: is endoscopy always indicated? A perspective from a Sierra Leone experience. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 69, 1191-2; author reply 1192-3	5.2	4
135	Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , <b>2009</b> , 60, 254-63	10.2	15
134	Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , <b>2009</b> , 59, 135-53	10.2	126
133	Use of Antisecretory Medication after Antireflux Surgery for Patients with Gastroesophageal Reflux Disease (GERD): A Systematic Review of Randomized Control Trials (RCTs). <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, S25	0.7	3
132	Oesophageal corrosive injuries in children: a forgotten social and health challenge in developing countries. <i>Bulletin of the World Health Organization</i> , <b>2009</b> , 87, 950-4	8.2	61

131	A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 917-30	6.1	153
130	Proton pump inhibitors: the beginning of the end or the end of the beginning?. <i>Current Opinion in Pharmacology</i> , <b>2008</b> , 8, 677-84	5.1	57
129	NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?. <i>Gut</i> , <b>2008</b> , 57, 145-8	19.2	43
128	New drugs to suppress acid secretion: current and future developments. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2007</b> , 4, 155-163		5
127	Determinants of the short-term gastric damage caused by NSAIDs in man. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 95-106	6.1	57
126	The burden of constipation on quality of life: results of a multinational survey. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 227-36	6.1	240
125	Corrosive esophageal injuries in children. A shortlived experience in Sierra Leone. <i>International Journal of Pediatric Otorhinolaryngology</i> , <b>2007</b> , 71, 1597-604	1.7	32
124	'Rescue' therapies for the management of Helicobacter pylori infection. <i>Digestive Diseases</i> , <b>2006</b> , 24, 113-30	3.2	41
123	Eradication of Helicobacter pylori: are rifaximin-based regimens effective?. <i>Digestion</i> , <b>2006</b> , 73 Suppl 1, 129-35	3.6	21
122	Treatment of functional bowel disorders: is there room for antibiotics?. <i>Digestion</i> , <b>2006</b> , 73 Suppl 1, 38-46	3.6	15
121	Management of colonic diverticular disease. <i>Digestion</i> , <b>2006</b> , 73 Suppl 1, 58-66	3.6	25
120	Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?. <i>Digestion</i> , <b>2006</b> , 73 Suppl 1, 136-50	3.6	67
119	Acid suppression therapy: where do we go from here?. <i>Digestive Diseases</i> , <b>2006</b> , 24, 11-46	3.2	64
118	Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. <i>Digestion</i> , <b>2006</b> , 73 Suppl 1, 13-27	3.6	94
117	Dysphagia aortica: a neglected symptom of aorto-esophageal fistula. <i>Digestive and Liver Disease</i> , <b>2006</b> , 38, 51-4	3.3	10
116	Review article: the opportunities and benefits of extended acid suppression. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23 Suppl 2, 23-34	6.1	26
115	Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle. <i>Digestive and Liver Disease</i> , <b>2005</b> , 37, 468-74	3.3	8
114	Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. <i>Chemotherapy</i> , <b>2005</b> , 51 Suppl 1, 36-66	3.2	159



113	Myths and misconceptions about chronic constipation. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 232-42	0.7	341
112	Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. <i>Chemotherapy</i> , <b>2005</b> , 51 Suppl 1, 122-30	3.2	18
111	Antisecretory Drugs for Eradication of Helicobacter pylori: Antibacterial Activity and Synergism with Antimicrobial Agents <b>2004</b> , 11, 134-178		
110	Does the learning phase influence the late outcome of patients with gastroesophageal reflux disease after laparoscopic fundoplication?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2004</b> , 18, 266-71	5.2	7
109	Towards the ideal regimen for Helicobacter pylori eradication: the search continues. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 243-7	3.3	13
108	Can gangrenous cholecystitis be prevented?: a plea against a "wait and see" attitude. <i>Journal of Clinical Gastroenterology</i> , <b>2004</b> , 38, 710-6	3	21
107	Endoscopic treatment of gastro-oesophageal reflux disease (GORD): a systematic review. <i>Digestive and Liver Disease</i> , <b>2003</b> , 35, 818-38	3.3	15
106	Dysphagia and clinical outcome after laparoscopic Nissen or Rossetti fundoplication: sequential prospective study. <i>World Journal of Surgery</i> , <b>2002</b> , 26, 1106-11	3.3	12
105	Quality of life for patients with gastroesophageal reflux disease 2 years after laparoscopic fundoplication. Evaluation of the results obtained during the initial experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2002</b> , 16, 1555-60	5.2	24
104	Early esophageal transit study after laparoscopic fundoplication: how useful is it?. <i>American Journal of Surgery</i> , <b>2002</b> , 183, 226-31	2.7	7
103	Different affinity states of CCK(1) receptors on pancreatic acini and gastric smooth muscle in the rat. <i>Journal of Physiology (Paris)</i> , <b>2001</b> , 95, 391-8		4
102	Improving opportunities for effective management of gastro-oesophageal reflux disease. <i>Digestive and Liver Disease</i> , <b>2001</b> , 33, 720-30	3.3	5
101	Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. <i>Digestive and Liver Disease</i> , <b>2001</b> , 33, 600-6	3.3	22
100	New therapeutic modalities for benign oesophageal disease: an overview. <i>Digestive and Liver Disease</i> , <b>2001</b> , 33, 260-5	3.3	3
99	Current trends in the management of achalasia. <i>Digestive and Liver Disease</i> , <b>2001</b> , 33, 266-77	3.3	24
98	Somatostatin analogs for cancer treatment and diagnosis: an overview. <i>Chemotherapy</i> , <b>2001</b> , 47 Suppl 2, 1-29	3.2	63
97	Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>1999</b> , 13 Suppl A, 50A-65A		46
96	Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. <i>Digestion</i> , <b>1999</b> , 60 Suppl 3, 1-16	3.6	54

95	Bismuth Compounds for Eradication of <i>Helicobacter pylori</i> : Pharmacology and Safety <b>1999</b> , 11, 87-127		11
94	Antisecretory Drugs for Eradication of <i>Helicobacter pylori</i> : Antibacterial Activity and Synergism with Antimicrobial Agents <b>1999</b> , 11, 136-181		10
93	Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. <i>Italian Journal of Gastroenterology and Hepatology</i> , <b>1999</b> , 31 Suppl 1, S63-72		12
92	Different actions of CCK on pancreatic and gastric growth in the rat: effect of CCK(A) receptor blockade. <i>British Journal of Pharmacology</i> , <b>1998</b> , 124, 435-40	8.6	17
91	DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. <i>Cytometry</i> , <b>1998</b> , 34, 257-63		74
90	Effects of tablet and effervescent formulations of ranitidine 75 mg and cimetidine 200 mg on gastric acidity and oesophageal acid exposure in healthy humans. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1998</b> , 12, 1155-61	6.1	6
89	Treatment of gastro-oesophageal reflux disease in adults. <i>BMJ: British Medical Journal</i> , <b>1998</b> , 316, 1720-3		56
88	Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. <i>American Journal of Physiology - Renal Physiology</i> , <b>1998</b> , 275, G1266-73	5.1	40
87	Pharmacological stimulation of gastrointestinal motility: where we are and where are we going?. <i>Digestive Diseases</i> , <b>1997</b> , 15 Suppl 1, 112-36	3.2	16
86	Specific adaptation of gastric emptying to diets with differing protein content in the rat: is endogenous cholecystokinin implicated?. <i>Gut</i> , <b>1997</b> , 41, 612-8	19.2	36
85	Functional Ultrasonography of the Digestive Tract <b>1997</b> , 24, 342-383		1
84	Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. <i>Journal of Physiology (Paris)</i> , <b>1997</b> , 91, 257-64		3
83	Camostate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists. <i>European Journal of Pharmacology</i> , <b>1996</b> , 306, 153-9	5.3	16
82	The place of octreotide in the medical management of the dumping syndrome. <i>Digestion</i> , <b>1996</b> , 57 Suppl 1, 114-8	3.6	18
81	Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1996</b> , 10, 411-9	6.1	32
80	Inhibition of acetylcholine induced intestinal motility by interleukin 1 beta in the rat. <i>Gut</i> , <b>1996</b> , 39, 470-49.2		43
79	In vitro contractile effects of short chain fatty acids in the rat terminal ileum. <i>Gut</i> , <b>1996</b> , 38, 53-8	19.2	31
78	The Management of Nonvariceal Upper Digestive Bleeding: Is There a Role for Somatostatin and Its Analogues?. <i>Progress in Basic and Clinical Pharmacology</i> , <b>1996</b> , 10, 139-150		

77	A new technique for continuous measurement and recording of gastric potential difference in the rat: evaluation of NSAID-induced gastric mucosal damage. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>1995</b> , 34, 63-72	1.7	13
76	Reflux related symptoms in patients with normal oesophageal exposure to acid. <i>Gut</i> , <b>1995</b> , 37, 457-64	19.2	175
75	Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa?. <i>Digestive Diseases</i> , <b>1995</b> , 13 Suppl 1, 9-39	3.2	43
74	Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. <i>Chemotherapy</i> , <b>1995</b> , 41 Suppl 1, 48-81	3.2	45
73	Distinct receptors mediate gastrin-releasing peptide and neuromedin beta-induced delay of gastric of liquids in rats. <i>European Journal of Pharmacology</i> , <b>1995</b> , 286, 109-12	5.3	21
72	Oesophageal sensitivity to acid in patients with non-cardiac chest pain: is the oesophagus hypersensitive?. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1995</b> , 7, 1152-9	2.2	11
71	Transmucosal potential difference as an index of esophageal mucosal integrity. <i>Digestion</i> , <b>1995</b> , 56 Suppl 1, 51-60	3.6	14
70	Prevention of NSAID-induced gastroduodenal mucosal injury: meta-analysis of clinical trials with misoprostol and H2-receptor antagonists. <i>Digestive Diseases</i> , <b>1995</b> , 13 Suppl 1, 62-74	3.2	24
69	Gastric Emptying in Gastroesophageal Reflux Disease and Other Functional Esophageal Disorders. <i>Frontiers of Gastrointestinal Research</i> , <b>1994</b> , 22, 223-259		5
68	Esophageal pH Monitoring. <i>Frontiers of Gastrointestinal Research</i> , <b>1994</b> , 22, 71-108		9
67	Placebo and placebo effect: their impact on the evaluation of drug response in patients. <i>Digestive Diseases</i> , <b>1994</b> , 12, 368-77	3.2	17
66	Effect of CCK and its antagonists on gastric emptying. <i>Journal of Physiology (Paris)</i> , <b>1993</b> , 87, 291-300		37
65	Clinical pharmacology of active variceal bleeding. <i>Digestive Diseases</i> , <b>1992</b> , 10 Suppl 1, 16-29	3.2	7
64	Effect of devazepide on caerulein and camostate induced delay of gastric emptying in the rat. <i>Pharmacological Research</i> , <b>1992</b> , 25, 288-289	10.2	2
63	Effect of cisapride on gastric emptying of solids and postprandial esophageal exposure to acid in healthy volunteers. <i>Pharmacological Research</i> , <b>1992</b> , 25, 212-213	10.2	1
62	Effect of nizatidine on salivary secretion in the rat. <i>Pharmacological Research</i> , <b>1992</b> , 25, 286-287	10.2	
61	Sucalfate and Other Mucosal Protective Compounds: Pharmacology and Potential in the Treatment of Esophageal Lesions. <i>Frontiers of Gastrointestinal Research</i> , <b>1992</b> , 20, 317-346		3
60	Acid-Lowering Drugs in the Treatment of Gastroesophageal Reflux Disease: An Overview. <i>Frontiers of Gastrointestinal Research</i> , <b>1992</b> , 20, 129-152		

59	Metoclopramide: Is There Still a Place in the Treatment of Gastroesophageal Reflux Disease?. <i>Frontiers of Gastrointestinal Research</i> , <b>1992</b> , 20, 17-29		
58	Antacids and Alginates in the Treatment of Gastroesophageal Reflux Disease: How Do They Work and How Much Are They Clinically Useful?. <i>Frontiers of Gastrointestinal Research</i> , <b>1992</b> , 20, 153-181		3
57	Cholecystokinin Antagonists and Motilides: Pharmacology and Potential in the Treatment of Gastroesophageal Reflux Disease and Other Digestive Motor Disorders. <i>Frontiers of Gastrointestinal Research</i> , <b>1992</b> , 20, 90-128		8
56	Gastroesophageal reflux disease and pH monitoring. <i>Current Opinion in Gastroenterology</i> , <b>1990</b> , 6, 608-620		2
55	Columnar-lined (Barrett's) esophagus. <i>Current Opinion in Gastroenterology</i> , <b>1990</b> , 6, 580-585	3	2
54	Simultaneous measurement and recording of gastric potential difference and intragastric pH in man. <i>Digestive Diseases</i> , <b>1990</b> , 8 Suppl 1, 60-70	3.2	6
53	Gastric Emptying Measurement in Man. <i>Frontiers of Gastrointestinal Research</i> , <b>1990</b> , 17, 198-246		15
52	Bombesin-induced pancreatic secretion and growth in rats: effect of proglumide, spantide and ranitidine. <i>International Journal of Tissue Reactions</i> , <b>1990</b> , 12, 299-307		2
51	Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans. <i>European Journal of Clinical Pharmacology</i> , <b>1989</b> , 37, 483-6	2.8	3
50	Dual effect of bombesin and gastrin releasing peptide on gastric emptying in conscious cats. <i>Peptides</i> , <b>1989</b> , 10, 281-7	3.8	4
49	Pancreatic secretory and trophic response to caerulein in rats: effect of proglumide and lorglumide. <i>Fundamental and Clinical Pharmacology</i> , <b>1989</b> , 3, 295-306	3.1	4
48	Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. <i>British Journal of Pharmacology</i> , <b>1989</b> , 96, 661-9	8.6	24
47	Effect of cimetropium bromide and other antispasmodic compounds on in vitro guinea-pig gallbladder. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , <b>1989</b> , 11, 323-9		3
46	Mucosal protective agents: why forget pirenzepine?. <i>Digestive Diseases and Sciences</i> , <b>1988</b> , 33, 1500		4
45	Effect of Bombesin on Insulin Release in Man. <i>Annals of the New York Academy of Sciences</i> , <b>1988</b> , 547, 527-529	6.5	1
44	Different effects of bombesin on glucose- and tolbutamide-induced insulin release in man. <i>British Journal of Pharmacology</i> , <b>1988</b> , 94, 1023-8	8.6	2
43	Pharmacological bases of the medical treatment of gastroesophageal reflux disease. <i>Digestive Diseases</i> , <b>1988</b> , 6, 117-48	3.2	18
42	Effect of bombesin and its mammalian counterpart, GRP, on exocrine pancreas in the rat. <i>Digestion</i> , <b>1988</b> , 41, 229-36	3.6	12

41	Caerulein in supramaximal doses fails to stimulate pancreatic growth, but it forces secretory granulopoiesis. <i>Acta Physiologica Hungarica</i> , <b>1988</b> , 71, 99-106		5
40	Effect of bombesin on glucose-induced insulin release in humans. <i>Digestion</i> , <b>1987</b> , 37, 114-24	3.6	6
39	Relaxant effect of the H2-receptor antagonist oxmetidine on guinea-pig and human airways. <i>British Journal of Pharmacology</i> , <b>1987</b> , 90, 523-30	8.6	4
38	Antisecretory and antiulcer effect of the H2-receptor antagonist famotidine in the rat: comparison with ranitidine. <i>British Journal of Pharmacology</i> , <b>1987</b> , 92, 153-9	8.6	14
37	Inhibition of gastric acid secretion by adenosine receptor stimulation in the rat. <i>Pharmacology</i> , <b>1987</b> , 34, 264-8	2.3	19
36	Bombesin promotes pancreatic growth in suckling rats. <i>Experientia</i> , <b>1987</b> , 43, 201-2		13
35	Effect of famotidine and ranitidine on gastric secretion and emptying in the rat. <i>Drug Development Research</i> , <b>1987</b> , 11, 37-43	5.1	2
34	Effect of somatostatin 14 on pure human pancreatic secretion. <i>Digestive Diseases and Sciences</i> , <b>1987</b> , 32, 1065-70	4	35
33	The effect of the new H2-receptor antagonist mifentidine on gastric secretion, gastric emptying and experimental gastric and duodenal ulcers in the rat: comparison with cimetidine and ranitidine. <i>Digestion</i> , <b>1986</b> , 33, 7-16	3.6	15
32	Effect of somatostatin and thyrotropin-releasing hormone on cholecystokinin-induced gallbladder emptying. <i>Digestive Diseases and Sciences</i> , <b>1986</b> , 31, 1345-50	4	27
31	Oxygen free radicals interact with indomethacin to cause gastrointestinal injury. <i>Agents and Actions</i> , <b>1986</b> , 17, 484-8		56
30	Effect of bombesin on basal and stimulated secretion of some pituitary hormones in humans. <i>Hormone Research</i> , <b>1986</b> , 23, 129-35		13
29	Effect of caerulein on pituitary response to TRH in humans. <i>Hormone Research</i> , <b>1986</b> , 24, 295-301		2
28	Opposite effects of bombesin on insulin and gastrin response to food in humans. <i>Gut</i> , <b>1986</b> , 27, 499-504	19.2	5
27	Bombesin inhibits growth hormone response to insulin-induced hypoglycemia in humans. <i>Brain Research</i> , <b>1986</b> , 371, 187-9	3.7	6
26	Cimetidine inhibition of dimaprit-induced writhing in the rat. <i>Pharmacology</i> , <b>1986</b> , 32, 237-40	2.3	3
25	Inhibition of pancreatic secretory and trophic response to caerulein by the H2-receptor antagonist ranitidine in the rat. <i>Digestion</i> , <b>1985</b> , 31, 177-82	3.6	9
24	Comparative effects of vasoactive intestinal peptide and secretin on exocrine pancreatic secretion in the cat. <i>Regulatory Peptides</i> , <b>1985</b> , 12, 125-32		2

23	Inhibition of the histamine-stimulated adenylate cyclase activity of guinea pig gastric cells by the H <sub>2</sub> -receptor antagonists cimetidine, oxmetidine and SKF 93479. <i>Pharmacology</i> , <b>1984</b> , 28, 268-74	2.3	6
22	Bombesin and Gastric Emptying. <i>Gastroenterology</i> , <b>1984</b> , 86, 1629-1630	13.3	2
21	Plasma levels and renal removal of gastrin after acute hepatic ischemia in dogs. <i>Journal of Endocrinological Investigation</i> , <b>1984</b> , 7, 201-5	5.2	1
20	Inhibition of gastric emptying and secretion by pirenzepine and atropine in rats. <i>European Journal of Pharmacology</i> , <b>1984</b> , 101, 193-200	5.3	14
19	Inhibition of Gastric Emptying by Angiotensin in the Rat and its Antagonism by Saralasin. <i>Journal of Urology</i> , <b>1984</b> , 131, 1025-1025	2.5	
18	Effects of Bombesin on Gastric Emptying of Solids in Normal and Antrectomized Subjects: Evidence for an Action at the Distal Stomach <b>1984</b> , 149-156		1
17	Impaired TSH response to TRH after intravenous ranitidine in man. <i>Experientia</i> , <b>1983</b> , 39, 109-10		5
16	Renal removal of glucagon and insulin after acute hepatic ischaemia in dogs. <i>Diabète &amp; Métabolisme</i> , <b>1983</b> , 9, 3-8		3
15	Inhibition of gastric emptying by bombesin in man. <i>Digestion</i> , <b>1982</b> , 23, 128-31	3.6	28
14	Histamine H <sub>2</sub> -antagonists modify gastric emptying in the rat. <i>British Journal of Pharmacology</i> , <b>1982</b> , 77, 443-8	8.6	45
13	Ranitidine delays gastric emptying of solids in man. <i>British Journal of Clinical Pharmacology</i> , <b>1982</b> , 13, 252-3	3.8	20
12	Different effects of the H <sub>2</sub> -antagonists on gastric emptying in the rat. <i>Experientia</i> , <b>1982</b> , 38, 385-6		8
11	Different effects of cimetidine and ranitidine on gastric emptying in rats and man. <i>Agents and Actions</i> , <b>1982</b> , 12, 172-3		23
10	Effect of substance P and its natural analogues on gastric emptying of the conscious rat. <i>British Journal of Pharmacology</i> , <b>1981</b> , 72, 221-3	8.6	16
9	The effect of bombesin on gastric emptying of solids in man. <i>Peptides</i> , <b>1981</b> , 2 Suppl 2, 199-203	3.8	12
8	Effects of alkyl analogues of histamine and metiamide on the isolated guinea pig heart. <i>Pharmacology</i> , <b>1981</b> , 22, 101-7	2.3	10
7	Failure of drugs acting on H <sub>2</sub> -receptors to modify plasma prolactin levels in pituitary adenomas: evidence for a suprapituitary locus of action. <i>International Pharmacopsychiatry</i> , <b>1981</b> , 16, 79-83		
6	Effect of histamine and related compounds on gastric emptying of the conscious rat. <i>Pharmacology</i> , <b>1981</b> , 23, 185-91	2.3	12

5	Effect of acute and chronic cimetidine administration on glucose tolerance and insulin secretion in man. <i>Hormone Research</i> , <b>1981</b> , 15, 228-36		6
4	Bombesin delays gastric emptying in the rat. <i>Digestion</i> , <b>1981</b> , 21, 104-6	3.6	43
3	Caerulein delays gastric emptying of solids in man. <i>Archives Internationales De Pharmacodynamie Et De Therapie</i> , <b>1981</b> , 249, 98-105		8
2	Action of caerulein on gastric emptying of the conscious rat. <i>Archives Internationales De Pharmacodynamie Et De Therapie</i> , <b>1980</b> , 246, 286-94		69
1	Effects of cimetidine on the secretion of some pituitary hormones. <i>Pharmacology</i> , <b>1979</b> , 19, 111-5	2.3	6